Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Pancreastatin (PST) is known as the peptide which inhibits first phase of glucose-stimulated insulin secretion. Fasting plasma PST levels and responses of PST after oral glucose ingestion in patients with non-insulin-dependent diabetes mellitus (NIDDM) were studied with human PST-specific radioimmunoassay. Fasting plasma PST in NIDDM patients was not different from healthy controls, although a slightly higher level of PST was observed in patients treated with sulfonylurea among NIDDM patients. No significant increase in plasma PST was observed after a glucose ingestion in healthy controls. In contrast, plasma PST levels in NIDDM patients rose significantly after glucose ingestion. These results suggest a possible pathophysiological role for PST in NIDDM.
Funakoshi
A
A
National Kyushu Cancer Center, Japan.
Tateishi
K
K
Shinozaki
H
H
Matsumoto
M
M
Wakasugi
H
H
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D053379:Chromogranin A; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D000078790:Insulin Secretion; D010187:Pancreatic Hormones / Q000097:blood*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D001786:Blood Glucose; D053379:Chromogranin A; D007328:Insulin; D010187:Pancreatic Hormones; D013453:Sulfonylurea Compounds; C050836:pancreastatin; D005947:Glucose